Cara Therapeutic
Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelike… Read more
Cara Therapeutic (CARA) - Net Assets
Latest net assets as of December 2024: $-4.59 Million USD
Based on the latest financial reports, Cara Therapeutic (CARA) has net assets worth $-4.59 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($43.83 Million) and total liabilities ($48.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.59 Million |
| % of Total Assets | -10.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | -101.84% |
| 10-Year Change | -104.37% |
| Growth Volatility | 143.25 |
Cara Therapeutic - Net Assets Trend (2011–2024)
This chart illustrates how Cara Therapeutic's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cara Therapeutic (2011–2024)
The table below shows the annual net assets of Cara Therapeutic from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-4.59 Million | -108.05% |
| 2023-12-31 | $57.09 Million | -64.05% |
| 2022-12-31 | $158.78 Million | -30.21% |
| 2021-12-31 | $227.52 Million | -8.63% |
| 2020-12-31 | $249.00 Million | +33.36% |
| 2019-12-31 | $186.71 Million | +39.72% |
| 2018-12-31 | $133.63 Million | +53.99% |
| 2017-12-31 | $86.78 Million | +71.08% |
| 2016-12-31 | $50.73 Million | -51.71% |
| 2015-12-31 | $105.04 Million | +103.33% |
| 2014-12-31 | $51.66 Million | +348.81% |
| 2013-12-31 | $11.51 Million | +371.96% |
| 2012-12-31 | $2.44 Million | -60.04% |
| 2011-12-31 | $6.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cara Therapeutic's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 70249900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | % |
| Other Components | $751.01 Million | % |
| Total Equity | $-4.59 Million | 100.00% |
Cara Therapeutic Competitors by Market Cap
The table below lists competitors of Cara Therapeutic ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mooncor Oil & Gas Corp
V:MOO
|
$8.11 Million |
|
KESM Industries Bhd
KLSE:9334
|
$8.12 Million |
|
NanoCMS Co. Ltd.
KQ:247660
|
$8.12 Million |
|
Suraj Limited
NSE:SURAJLTD
|
$8.12 Million |
|
Wijaya Karya Bangunan Gedung Tbk PT
JK:WEGE
|
$8.11 Million |
|
Jufan Industrial Co., Ltd.
TWO:4584
|
$8.11 Million |
|
Heart Test Laboratories Inc. Common Stock
NASDAQ:HSCS
|
$8.11 Million |
|
Cambium Bio Ltd
AU:CMB
|
$8.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cara Therapeutic's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 57,085,000 to -4,593,000, a change of -61,678,000 (-108.0%).
- Net loss of 70,867,000 reduced equity.
- Other comprehensive income increased equity by 260,000.
- Other factors increased equity by 8,929,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-70.87 Million | -1542.93% |
| Other Comprehensive Income | $260.00K | +5.66% |
| Other Changes | $8.93 Million | +194.4% |
| Total Change | $- | -108.05% |
Book Value vs Market Value Analysis
This analysis compares Cara Therapeutic's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.99 | $18.25 | x |
| 2012-12-31 | $0.39 | $18.25 | x |
| 2013-12-31 | $0.53 | $18.25 | x |
| 2014-12-31 | $2.46 | $18.25 | x |
| 2015-12-31 | $4.27 | $18.25 | x |
| 2016-12-31 | $1.86 | $18.25 | x |
| 2017-12-31 | $2.78 | $18.25 | x |
| 2018-12-31 | $3.72 | $18.25 | x |
| 2019-12-31 | $4.38 | $18.25 | x |
| 2020-12-31 | $5.20 | $18.25 | x |
| 2021-12-31 | $4.49 | $18.25 | x |
| 2022-12-31 | $2.96 | $18.25 | x |
| 2023-12-31 | $1.05 | $18.25 | x |
| 2024-12-31 | $-0.10 | $18.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cara Therapeutic utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -992.95%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-78.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -160.65% | 0.00% | 0.00x | 1.75x | $-10.42 Million |
| 2012 | -257.11% | -526.97% | 0.21x | 2.27x | $-6.51 Million |
| 2013 | -34.43% | -33.12% | 0.66x | 1.57x | $-5.11 Million |
| 2014 | -34.35% | -558.55% | 0.06x | 1.08x | $-22.91 Million |
| 2015 | -23.50% | -649.22% | 0.03x | 1.06x | $-35.19 Million |
| 2016 | -112.92% | -66604.65% | 0.00x | 1.26x | $-62.35 Million |
| 2017 | -66.98% | -6380.35% | 0.01x | 1.12x | $-66.80 Million |
| 2018 | -55.39% | -549.51% | 0.07x | 1.43x | $-87.38 Million |
| 2019 | -56.97% | -534.91% | 0.09x | 1.25x | $-125.04 Million |
| 2020 | 3.38% | 6.23% | 0.50x | 1.09x | $-16.49 Million |
| 2021 | -38.76% | -382.98% | 0.09x | 1.09x | $-110.95 Million |
| 2022 | -52.53% | -199.23% | 0.23x | 1.15x | $-99.29 Million |
| 2023 | -207.61% | -565.21% | 0.17x | 2.20x | $-124.22 Million |
| 2024 | 0.00% | -992.95% | 0.16x | 0.00x | $-70.41 Million |
Industry Comparison
This section compares Cara Therapeutic's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cara Therapeutic (CARA) | $-4.59 Million | -160.65% | N/A | $8.11 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |